Dublin-based biotechnology startup Aerska has announced a $21 million seed financing led by Age1, Backed VC, and Speedinvest to develop RNA interference (RNAi) therapeutics targeting neurological diseases. Aerska’s antibody-oligonucleotide conjugate (AOC) platform focuses on delivering RNAi drugs across the blood-brain barrier, aiming to address currently underserved neurodegenerative conditions such as genetic forms of Alzheimer’s and Parkinson’s disease. The funding will support preclinical validation and candidate nomination efforts.